Skip to main content
SpringerLink
Log in
Book cover

Acute Leukemias II pp 103–109Cite as

Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia:Augmentation of LAK-Cell Cytotoxicity by Combinations of Lymphokines or Cytokines

  • Conference paper

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 33))

Abstract

Adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) or induction of cytotoxic mechanisms by IL-2 alone was shown to be a promising approach in cancer therapy [1–11]. Most of the available data come from experimental and clinical studies of solid tumors, while only little is known about the effect of LAK cells against human leukemia [12–14]. Leukemia patients have been reported to have a deficiency in natural killer (NK) cell functions which may contribute to leukemogenesis. Experimental data on correcting this deficiency by IL-2 make it possible that adoptive immunotherapy of leukemia patients may be of great value in the treatment of human leukemia [15, 16]. In the present study we investigated the ability of LAK cells to lyse fresh human leukemia cells in vitro and evaluated the augmentation of cytotoxic mechanisms by combined application of IL-2 and other lymphokines or cytokines and by inhibition of prostaglandin synthesis during the activation process.

Supported by the Deutsche Krebshilfe e.V./Mildred Scheel Stiftung für Krebsforschung, Bonn (W 19/87/Te 1).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492

    Article  PubMed  CAS  Google Scholar 

  2. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma:phase I trial. Cancer Res 46:2101–2104

    PubMed  CAS  Google Scholar 

  3. Lotze MT, Matory YL, Rayner AA, Etting¬hausen SE, Vetto JT, Seipp CA, Rosenberg

    Article  PubMed  CAS  Google Scholar 

  4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    Article  PubMed  CAS  Google Scholar 

  5. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion of recombinant in-terleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    Article  PubMed  CAS  Google Scholar 

  6. Ingram M, Shelden CH, Jacques S, Skillen RG, Bradley WG, Techy GB, Freshwater DB, Abts RM, Rand RW (1987) Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489–498

    PubMed  CAS  Google Scholar 

  7. Rosenberg SA (1988) Cancer therapy with interleukin-2:immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 6:403–405

    PubMed  CAS  Google Scholar 

  8. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclo-phosphamide and low-dose intravenous in-terleukin-2 in disseminated melanoma. J Clin Oncol 6:409–424

    PubMed  CAS  Google Scholar 

  9. Sosman JA, Kohler PC, Hank J, Moor KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2:responses of renal carcinoma with acceptable toxicity. JNCI 80:60–63

    PubMed  CAS  Google Scholar 

  10. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 108:518–523

    PubMed  CAS  Google Scholar 

  11. Gambacorti-Passerini C, Radrizzani M, Marolda R, Belli F, Sciorelli G, Galazka AR, Schindler JD, Cascinelli N, Parmiani G (1988) In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin-2. Int J Cancer 41:700–706

    Article  PubMed  CAS  Google Scholar 

  12. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938–948

    PubMed  CAS  Google Scholar 

  13. Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727

    PubMed  CAS  Google Scholar 

  14. Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R (1988) In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2:50–54

    PubMed  CAS  Google Scholar 

  15. Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716

    PubMed  CAS  Google Scholar 

  16. Lotzova E, Savary CA, Herberman RB, Dicke KA (1986) Can NK cells play a role in therapy of leukemia? Nat Immun Cell Growth Regul 5:61–63

    PubMed  CAS  Google Scholar 

  17. Ludwig W-D, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H (1988) Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. Blood 71:1518–1528

    PubMed  CAS  Google Scholar 

  18. Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K (1985) Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-gamma (IFN-03γ). J Immunol 134:3124–3129

    PubMed  CAS  Google Scholar 

  19. Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes:effect of tumor necrosis factor-alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788–792

    PubMed  CAS  Google Scholar 

  20. Scheurich P, Thoma B, Uecer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha:induction of TNF receptors on human T cells and TNF-alpha mediated enhancement of T cell responses. J Immunol 138:1786–1790

    PubMed  CAS  Google Scholar 

  21. Nii A, Sone S, Utsugi T, Yanagawa H, Ogura T (1988) Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induc-tion by monocytes, depending on their functional state. Int J Cancer 41:33–40

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Hematology and Oncology, University-hospital Steglitz, Free University of Berlin, Germany

    J. V. Teichmann, W. D. Ludwig, H. Seibt-Jung & E. Thiel

Authors
  1. J. V. Teichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. D. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Seibt-Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Internal Medicine and Pediatrics, University of Münster, Albert-Schweitzer-Straße 33, D-4400, Münster, Federal Republic of Germany

    T. Büchner , G. Schellong , W. Hiddemann  & J. Ritter , ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Teichmann, J.V., Ludwig, W.D., Seibt-Jung, H., Thiel, E. (1990). Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia:Augmentation of LAK-Cell Cytotoxicity by Combinations of Lymphokines or Cytokines. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74643-7_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50984-4

  • Online ISBN: 978-3-642-74643-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation